Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P40424

UPID:
PBX1_HUMAN

ALTERNATIVE NAMES:
Homeobox protein PBX1; Homeobox protein PRL

ALTERNATIVE UPACC:
P40424; B4DSC1; F5H4U9; Q5T488

BACKGROUND:
The Pre-B-cell leukemia transcription factor 1, known alternatively as Homeobox protein PRL, is a key transcriptional regulator. It binds specific DNA sequences to control gene expression, crucial for development and cellular differentiation. PBX1's interaction with HOX proteins and MEIS1 influences the transcriptional regulation of critical genes involved in cell development, including the activation of NFIL3 in natural killer cells and the regulation of CYP17A1 gene expression.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in congenital anomalies of the kidney and urinary tract syndrome, with manifestations such as renal failure and developmental delays, Pre-B-cell leukemia transcription factor 1 represents a significant target for therapeutic intervention. Exploring PBX1's function further could lead to innovative treatments for these complex conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.